AR086422A1 - Metodo para el tratamiento de tumores solidos avanzados, volasertib - Google Patents
Metodo para el tratamiento de tumores solidos avanzados, volasertibInfo
- Publication number
- AR086422A1 AR086422A1 ARP120101734A ARP120101734A AR086422A1 AR 086422 A1 AR086422 A1 AR 086422A1 AR P120101734 A ARP120101734 A AR P120101734A AR P120101734 A ARP120101734 A AR P120101734A AR 086422 A1 AR086422 A1 AR 086422A1
- Authority
- AR
- Argentina
- Prior art keywords
- volasertib
- solid tumors
- treatment
- hydrate
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Uso de Volasertib o una sal del mismo o un hidrato del mismo en combinación con Cisplatino o Carboplatino o una sal de los mismos o un hidrato de los mismos para tratar pacientes que sufren de tumores sólidos avanzados y/o metastásicos.Reivindicación 1: Volasertib o una sal del mismo o un hidrato del mismo aceptables para uso farmacéutico para el uso en el tratamiento de tumores sólidos avanzados y/o metastásicos caracterizado por la administración de 300 a 500 mg de Volasertib o una sal del mismo o un hidrato del mismo aceptables para uso farmacéutico en un día durante un ciclo de tratamiento de 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 ó 31 días.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11166365 | 2011-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086422A1 true AR086422A1 (es) | 2013-12-11 |
Family
ID=46149422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101734A AR086422A1 (es) | 2011-05-17 | 2012-05-16 | Metodo para el tratamiento de tumores solidos avanzados, volasertib |
Country Status (15)
Country | Link |
---|---|
US (1) | US9370535B2 (es) |
EP (1) | EP2709626A1 (es) |
JP (1) | JP2014513705A (es) |
KR (1) | KR20140025461A (es) |
CN (1) | CN103533940A (es) |
AR (1) | AR086422A1 (es) |
AU (1) | AU2012257760A1 (es) |
BR (1) | BR112013029484A2 (es) |
CA (1) | CA2836385A1 (es) |
CL (1) | CL2013003230A1 (es) |
EA (1) | EA201301269A1 (es) |
IL (1) | IL228908A0 (es) |
MX (1) | MX2013013014A (es) |
UY (1) | UY34076A (es) |
WO (1) | WO2012156380A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8303657A (nl) | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
DE3537761A1 (de) | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
JPH0276860A (ja) | 1987-10-05 | 1990-03-16 | Toyo Jozo Co Ltd | 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体 |
ES2058527T3 (es) | 1988-06-16 | 1994-11-01 | Smith Kline French Lab | Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen. |
FR2645152B1 (fr) | 1989-03-30 | 1991-05-31 | Lipha | 3h-pteridinones-4, procedes de preparation et medicaments les contenant |
US5043270A (en) | 1989-03-31 | 1991-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Intronic overexpression vectors |
CA2029651C (en) | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
GB9418499D0 (en) | 1994-09-14 | 1994-11-02 | Ciba Geigy Ag | Process for producing n-methylated organic pigments |
CO4410191A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
DK0825979T3 (da) | 1995-05-19 | 2001-05-07 | Novartis Ag | Fremgangsmåde til fremstilling af aromatiske nitroforbindelser |
US5698556A (en) | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
BR9711541A (pt) | 1996-09-23 | 1999-08-24 | Lilly Co Eli | Dihidrato d de olanzapina |
CA2340180A1 (en) | 1998-08-11 | 2000-02-24 | Pfizer Products Inc. | 1-aryl,-3-arylmethyl-1,8-naphthyridn-2(1h)-ones |
MXPA02001108A (es) | 1999-09-15 | 2002-08-20 | Warner Lambert Co | Pieridinonas como inhibidores de la cinasa. |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
AP2002002643A0 (en) | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
DE10018783A1 (de) | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
DE10058119A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Pepinotan-Kit |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CN1551881A (zh) | 2001-09-04 | 2004-12-01 | ���ָ��Ӣ��ķ�������Ϲ�˾ | 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途 |
BRPI0117198B1 (pt) | 2001-12-14 | 2018-03-13 | Merck Serono S.A. | Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase |
JP2005538048A (ja) | 2002-05-03 | 2005-12-15 | シエーリング アクチエンゲゼルシャフト | チアゾリジノン類、それらの生成及び医薬剤としての使用 |
FR2843114B1 (fr) | 2002-08-01 | 2004-09-10 | Poudres & Explosifs Ste Nale | Procede de monomethylation d'heterocycles azotes |
US20060074119A1 (en) | 2002-08-08 | 2006-04-06 | Andrews Clarence W Iii | Thiophene compounds |
US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
PT1539753E (pt) | 2002-09-16 | 2009-12-10 | Glaxo Group Ltd | Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase |
GB2398565A (en) | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
EA008778B1 (ru) | 2003-02-26 | 2007-08-31 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
PL1605971T3 (pl) | 2003-03-26 | 2010-10-29 | Wyeth Llc | Kompozycja immunogenna i sposoby |
AU2004231342A1 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
JP2007517828A (ja) | 2004-01-17 | 2007-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 気道の疾患を治療するための置換プテリジンの使用 |
DE102004002557A1 (de) | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
DE102004034623A1 (de) | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
EP1632493A1 (de) | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
JP2008510770A (ja) | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Plk阻害剤としての新規プテリジノン |
EP1784406A1 (de) | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
CA2617589A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
US20070117776A1 (en) | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
DK1948180T3 (da) | 2005-11-11 | 2013-05-27 | Boehringer Ingelheim Int | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
JP2009529038A (ja) | 2006-03-07 | 2009-08-13 | アストラゼネカ・アクチエボラーグ | ピペリジン誘導体、それらの製造法、治療剤としてのそれらの使用およびそれらを含む医薬組成物 |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
WO2009019205A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
JP4642085B2 (ja) | 2008-01-17 | 2011-03-02 | 日本下水道事業団 | 予測健全度を利用した施設管理および更新計画システム |
EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
ES2624622T3 (es) * | 2008-12-30 | 2017-07-17 | Rigel Pharmaceuticals, Inc. | Inhibidores de pirimidindiamina cinasa |
CA2755976C (en) | 2009-03-23 | 2020-04-07 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
WO2011022692A2 (en) | 2009-08-20 | 2011-02-24 | University Of Tennessee Research Foundation, The | Furanopyridine cannabinoid compounds and related methods of use |
US20130012465A1 (en) | 2009-12-07 | 2013-01-10 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
JP5841548B2 (ja) | 2010-02-17 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン、その製造方法及び使用 |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
-
2012
- 2012-05-09 US US13/467,147 patent/US9370535B2/en active Active
- 2012-05-15 CN CN201280023176.8A patent/CN103533940A/zh active Pending
- 2012-05-15 BR BR112013029484A patent/BR112013029484A2/pt not_active IP Right Cessation
- 2012-05-15 WO PCT/EP2012/058959 patent/WO2012156380A1/en active Application Filing
- 2012-05-15 MX MX2013013014A patent/MX2013013014A/es not_active Application Discontinuation
- 2012-05-15 EP EP12723424.3A patent/EP2709626A1/en not_active Ceased
- 2012-05-15 JP JP2014510769A patent/JP2014513705A/ja active Pending
- 2012-05-15 EA EA201301269A patent/EA201301269A1/ru unknown
- 2012-05-15 CA CA2836385A patent/CA2836385A1/en not_active Abandoned
- 2012-05-15 AU AU2012257760A patent/AU2012257760A1/en not_active Abandoned
- 2012-05-15 KR KR1020137030105A patent/KR20140025461A/ko not_active Application Discontinuation
- 2012-05-16 AR ARP120101734A patent/AR086422A1/es unknown
- 2012-05-17 UY UY0001034076A patent/UY34076A/es unknown
-
2013
- 2013-10-16 IL IL228908A patent/IL228908A0/en unknown
- 2013-11-11 CL CL2013003230A patent/CL2013003230A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2013003230A1 (es) | 2014-08-01 |
IL228908A0 (en) | 2013-12-31 |
CN103533940A (zh) | 2014-01-22 |
EA201301269A1 (ru) | 2014-05-30 |
MX2013013014A (es) | 2014-01-31 |
AU2012257760A1 (en) | 2013-10-31 |
UY34076A (es) | 2012-11-30 |
JP2014513705A (ja) | 2014-06-05 |
CA2836385A1 (en) | 2012-11-22 |
BR112013029484A2 (pt) | 2017-01-17 |
US9370535B2 (en) | 2016-06-21 |
US20130122111A1 (en) | 2013-05-16 |
EP2709626A1 (en) | 2014-03-26 |
WO2012156380A1 (en) | 2012-11-22 |
KR20140025461A (ko) | 2014-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
AR086390A1 (es) | Metodo para el tratamiento de malignidades solidas que incluyen malignidades solidas avanzadas o metastasicas | |
MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
BR112012009388A2 (pt) | derivados de apogossipolone como agentes anticâncer | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
MX2013010947A (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso. | |
PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
CL2016001361A1 (es) | Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa | |
MX2013008137A (es) | Procedimientos para tratar la prostatitis. | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |